• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
【24h】

Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.

机译：固定组合异山梨醇二硝酸盐-肼屈嗪用于心力衰竭中一氧化氮的增强治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The major advances in our understanding and management of heart failure (HF) in recent decades have not fully benefited all segments of our population. HF still represents a growing epidemic, especially for African-Americans, in whom the burden of HF is even greater. The recently reported beneficial effects of the fixed combination of isosorbide dinitrate and hydralazine (ISDN+HYD) in the African-American Heart Failure Trial (A-HeFT), has led to both the FDA approval of this agent and its endorsement by the latest HF guidelines. The properties of ISDN+HYD are well known as its components are mature agents, readily available in generic formulations that have been used for decades in other indications. However, fixed-dose ISDN+HYD represents the first drug to undergo targeted clinical development and to be approved for use in a specific ethnic group. As such, A-HeFT and the approval of ISDN+HYD represent landmark events that merit further scrutiny.
机译：最近几十年来，我们对心力衰竭（HF）的理解和管理方面的重大进步并未完全使我们所有人口受益。 HF仍然是一种日益严重的流行病，尤其是对于非洲裔美国人而言，在这些人中，HF的负担更大。最近在非裔美国人心力衰竭试验（A-HeFT）中报道了硝酸异山梨酯和肼苯哒嗪（ISDN + HYD）固定组合的有益作用，这导致FDA批准了该药并获得了最新HF的认可。准则。 ISDN + HYD的特性是众所周知的，因为它的成分是成熟的试剂，很容易以通用制剂的形式获得，而在其他适应症中已经使用了数十年。但是，固定剂量的ISDN + HYD代表了第一种经过有针对性的临床开发并被批准用于特定种族的药物。因此，A-HeFT和ISDN + HYD的批准代表了具有里程碑意义的事件，值得进一步审查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号